Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2021-01-22

AUTHORS

Emanuela Palmerini, Leanne L. Seeger, Marco Gambarotti, Alberto Righi, Peter Reichardt, Susan Bukata, Jean-Yves Blay, Tian Dai, Danielle Jandial, Piero Picci

ABSTRACT

BackgroundGiant cell tumor of bone (GCTB) is a rare osteoclastogenic stromal tumor. GCTB can rarely undergo malignant transformation. This post hoc analysis evaluated and classified malignancies in patients with GCTB who received denosumab.MethodsThis analysis was conducted on patients with pathologically confirmed GCTB and measurable active disease treated with denosumab 120 mg subcutaneously once every 4 weeks, with loading doses on study days 8 and 15, as part of a phase 2, open-label, multicenter study. We identified potential cases of malignancy related to GCTB through an independent multidisciplinary review or medical history, associated imaging or histopathologic reports, and disease course. The findings were summarized and no statistical analysis was performed.ResultsTwenty of five hundred twenty-six patients (3.8%) who received at least one dose of denosumab were misdiagnosed with GCTB that was later discovered to be malignancies: five primary malignant GCTB, five secondary malignant GCTB, four sarcomatous transformations, and six patients with other malignancies (giant cell-rich osteosarcoma, undifferentiated pleomorphic sarcoma, spindle cell sarcoma, osteogenic sarcoma, phosphaturic mesenchymal tumor of mixed connective tissue type, and fibrosarcoma/malignant fibrous histiocytoma). Many malignancies were present before denosumab was initiated (8 definitive cases, 7 likely cases), excluding potential involvement of denosumab in these cases. Signs associated with potential misdiagnoses of GCTB included poor mineralization with denosumab treatment, rapid relapse in pain, or a failure of the typical dramatic improvement in pain normally observed with denosumab.ConclusionsAlthough rare, GCTB can undergo malignant transformation, and rates in this study were consistent with previous reports. Signs of poor mineralization or lack of response to denosumab treatment may warrant close monitoring.Trial registrationclinicaltrials.gov, (NCT00680992). Registered May 20, 2008. More... »

PAGES

89

Identifiers

URI

http://scigraph.springernature.com/pub.10.1186/s12885-020-07739-8

DOI

http://dx.doi.org/10.1186/s12885-020-07739-8

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1134796044

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/33482769


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Density Conservation Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Bone Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Denosumab", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Giant Cell Tumor of Bone", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Rate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.6292.f", 
          "name": [
            "Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Palmerini", 
        "givenName": "Emanuela", 
        "id": "sg:person.01210215667.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210215667.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "David Geffen School of Medicine, UCLA Health System, 200 UCLA Medical Plaza Suite 165-57, 90095, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "David Geffen School of Medicine, UCLA Health System, 200 UCLA Medical Plaza Suite 165-57, 90095, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Seeger", 
        "givenName": "Leanne L.", 
        "id": "sg:person.01352077720.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352077720.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gambarotti", 
        "givenName": "Marco", 
        "id": "sg:person.01334463454.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334463454.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.419038.7", 
          "name": [
            "Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Righi", 
        "givenName": "Alberto", 
        "id": "sg:person.01115347567.94", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115347567.94"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Interdisciplinary Oncology, Sarcoma Center Berlin-Brandenburg; HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany", 
          "id": "http://www.grid.ac/institutes/grid.491869.b", 
          "name": [
            "Department of Interdisciplinary Oncology, Sarcoma Center Berlin-Brandenburg; HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Reichardt", 
        "givenName": "Peter", 
        "id": "sg:person.01111517020.19", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111517020.19"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "David Geffen School of Medicine, UCLA Health System, 200 UCLA Medical Plaza Suite 165-57, 90095, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.19006.3e", 
          "name": [
            "David Geffen School of Medicine, UCLA Health System, 200 UCLA Medical Plaza Suite 165-57, 90095, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Bukata", 
        "givenName": "Susan", 
        "id": "sg:person.0760531564.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760531564.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Oncology, Leon Berard Center, 28, rue Laennec 2 69373 Lyon Cedex 08, Lyon, France", 
          "id": "http://www.grid.ac/institutes/grid.418116.b", 
          "name": [
            "Department of Medical Oncology, Leon Berard Center, 28, rue Laennec 2 69373 Lyon Cedex 08, Lyon, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Blay", 
        "givenName": "Jean-Yves", 
        "id": "sg:person.01336605441.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336605441.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Global Development (Oncology), Amgen Inc., One Amgen Center Drive, MS 38-2-B, 91320-1799, Thousand Oaks, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Global Development (Oncology), Amgen Inc., One Amgen Center Drive, MS 38-2-B, 91320-1799, Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dai", 
        "givenName": "Tian", 
        "id": "sg:person.016076070467.89", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016076070467.89"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Global Development (Oncology), Amgen Inc., One Amgen Center Drive, MS 38-2-B, 91320-1799, Thousand Oaks, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.417886.4", 
          "name": [
            "Global Development (Oncology), Amgen Inc., One Amgen Center Drive, MS 38-2-B, 91320-1799, Thousand Oaks, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Jandial", 
        "givenName": "Danielle", 
        "id": "sg:person.014366566313.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014366566313.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University, 40136, Bologna, Italy", 
          "id": "http://www.grid.ac/institutes/grid.6292.f", 
          "name": [
            "Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University, 40136, Bologna, Italy"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Picci", 
        "givenName": "Piero", 
        "id": "sg:person.0753274552.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753274552.44"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00428-009-0863-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020976032", 
          "https://doi.org/10.1007/s00428-009-0863-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00428-013-1435-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032421058", 
          "https://doi.org/10.1007/s00428-013-1435-z"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ng.2814", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049677077", 
          "https://doi.org/10.1038/ng.2814"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12957-018-1478-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1107111968", 
          "https://doi.org/10.1186/s12957-018-1478-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00428-012-1198-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026093835", 
          "https://doi.org/10.1007/s00428-012-1198-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s002640050201", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020784074", 
          "https://doi.org/10.1007/s002640050201"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s11864-014-0289-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010580624", 
          "https://doi.org/10.1007/s11864-014-0289-1"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1245/s10434-009-0803-z", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004194617", 
          "https://doi.org/10.1245/s10434-009-0803-z"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2021-01-22", 
    "datePublishedReg": "2021-01-22", 
    "description": "BackgroundGiant cell tumor of bone (GCTB) is a rare osteoclastogenic stromal tumor. GCTB can rarely undergo malignant transformation. This post hoc analysis evaluated and classified malignancies in patients with GCTB who received denosumab.MethodsThis analysis was conducted on patients with pathologically confirmed GCTB and measurable active disease treated with denosumab 120\u2009mg subcutaneously once every 4\u2009weeks, with loading doses on study days 8 and 15, as part of a phase 2, open-label, multicenter study. We identified potential cases of malignancy related to GCTB through an independent multidisciplinary review or medical history, associated imaging or histopathologic reports, and disease course. The findings were summarized and no statistical analysis was performed.ResultsTwenty of five hundred twenty-six patients (3.8%) who received at least one dose of denosumab were misdiagnosed with GCTB that was later discovered to be malignancies: five primary malignant GCTB, five secondary malignant GCTB, four sarcomatous transformations, and six patients with other malignancies (giant cell-rich osteosarcoma, undifferentiated pleomorphic sarcoma, spindle cell sarcoma, osteogenic sarcoma, phosphaturic mesenchymal tumor of mixed connective tissue type, and fibrosarcoma/malignant fibrous histiocytoma). Many malignancies were present before denosumab was initiated (8 definitive cases, 7 likely cases), excluding potential involvement of denosumab in these cases. Signs associated with potential misdiagnoses of GCTB included poor mineralization with denosumab treatment, rapid relapse in pain, or a failure of the typical dramatic improvement in pain normally observed with denosumab.ConclusionsAlthough rare, GCTB can undergo malignant transformation, and rates in this study were consistent with previous reports. Signs of poor mineralization or lack of response to denosumab treatment may warrant close monitoring.Trial registrationclinicaltrials.gov, (NCT00680992). Registered May 20, 2008.", 
    "genre": "article", 
    "id": "sg:pub.10.1186/s12885-020-07739-8", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1024632", 
        "issn": [
          "1471-2407"
        ], 
        "name": "BMC Cancer", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "21"
      }
    ], 
    "keywords": [
      "malignant GCTB", 
      "denosumab treatment", 
      "cell tumors", 
      "open-label phase 2 study", 
      "malignant transformation", 
      "study day 8", 
      "dose of denosumab", 
      "primary malignant GCTB", 
      "secondary malignant GCTB", 
      "phase 2 study", 
      "giant cell tumor", 
      "BackgroundGiant cell tumors", 
      "lack of response", 
      "denosumab 120", 
      "active disease", 
      "histopathologic reports", 
      "disease course", 
      "stromal tumors", 
      "multicenter study", 
      "rapid relapse", 
      "medical history", 
      "MethodsThis analysis", 
      "potential misdiagnoses", 
      "denosumab", 
      "sarcomatous transformation", 
      "close monitoring", 
      "GCTB", 
      "malignancy", 
      "day 8", 
      "patients", 
      "poor mineralization", 
      "tumors", 
      "potential involvement", 
      "pain", 
      "phase 2", 
      "potential cases", 
      "previous reports", 
      "multidisciplinary review", 
      "treatment", 
      "bone", 
      "signs", 
      "dramatic improvement", 
      "report", 
      "ResultsTwenty", 
      "relapse", 
      "statistical analysis", 
      "disease", 
      "misdiagnoses", 
      "doses", 
      "dose", 
      "ConclusionsAlthough", 
      "weeks", 
      "study", 
      "cases", 
      "involvement", 
      "imaging", 
      "review", 
      "failure", 
      "findings", 
      "course", 
      "response", 
      "analysis", 
      "history", 
      "rate", 
      "lack", 
      "post", 
      "improvement", 
      "monitoring", 
      "part", 
      "mineralization", 
      "transformation"
    ], 
    "name": "Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab", 
    "pagination": "89", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1134796044"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1186/s12885-020-07739-8"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "33482769"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1186/s12885-020-07739-8", 
      "https://app.dimensions.ai/details/publication/pub.1134796044"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_891.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1186/s12885-020-07739-8"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s12885-020-07739-8'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s12885-020-07739-8'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s12885-020-07739-8'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s12885-020-07739-8'


 

This table displays all metadata directly associated to this object as RDF triples.

313 TRIPLES      21 PREDICATES      122 URIs      105 LITERALS      24 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1186/s12885-020-07739-8 schema:about N05bf52290f8b4fb2806e71dff76b6c9b
2 N175ceccf0dad410ea731f422261b2400
3 N2a00979e149c4681b5e2d8c354add420
4 N30717925981d47e0b8e3eec64268a190
5 N4245fe257f7f453a8d029c2a59a73dcd
6 N5ef46b8c20394c41b7394e29ee69cb3f
7 N62c0d39eadbe4f12b7b3bc559e8d2006
8 N6fba124141954c15877fc7ad785f0ff4
9 N75e85855cbfd48b1a3c7884cb4c3e305
10 N7ebf944b20c1478183cae6c861f0038f
11 N9277589216a44ccb8989e3601a693a88
12 Na0eaf2c8fe104cf1af8ec1f94208e3a2
13 Nb50dafa54c694389b8ee55869aed05bc
14 Nbf73ea4f926944a68a86f272f1c8a05e
15 Nc53e7441003d4e32aced84792b548ccb
16 Ne1da1cb81c224893af51aab2f74529c9
17 Ned0f4db1f64343a7ba14ddd188ddf03c
18 anzsrc-for:11
19 anzsrc-for:1103
20 anzsrc-for:1112
21 schema:author Nfb93d8e3f8ba41de8d3b6b3fde5e947f
22 schema:citation sg:pub.10.1007/s002640050201
23 sg:pub.10.1007/s00428-009-0863-2
24 sg:pub.10.1007/s00428-012-1198-y
25 sg:pub.10.1007/s00428-013-1435-z
26 sg:pub.10.1007/s11864-014-0289-1
27 sg:pub.10.1038/ng.2814
28 sg:pub.10.1186/s12957-018-1478-3
29 sg:pub.10.1245/s10434-009-0803-z
30 schema:datePublished 2021-01-22
31 schema:datePublishedReg 2021-01-22
32 schema:description BackgroundGiant cell tumor of bone (GCTB) is a rare osteoclastogenic stromal tumor. GCTB can rarely undergo malignant transformation. This post hoc analysis evaluated and classified malignancies in patients with GCTB who received denosumab.MethodsThis analysis was conducted on patients with pathologically confirmed GCTB and measurable active disease treated with denosumab 120 mg subcutaneously once every 4 weeks, with loading doses on study days 8 and 15, as part of a phase 2, open-label, multicenter study. We identified potential cases of malignancy related to GCTB through an independent multidisciplinary review or medical history, associated imaging or histopathologic reports, and disease course. The findings were summarized and no statistical analysis was performed.ResultsTwenty of five hundred twenty-six patients (3.8%) who received at least one dose of denosumab were misdiagnosed with GCTB that was later discovered to be malignancies: five primary malignant GCTB, five secondary malignant GCTB, four sarcomatous transformations, and six patients with other malignancies (giant cell-rich osteosarcoma, undifferentiated pleomorphic sarcoma, spindle cell sarcoma, osteogenic sarcoma, phosphaturic mesenchymal tumor of mixed connective tissue type, and fibrosarcoma/malignant fibrous histiocytoma). Many malignancies were present before denosumab was initiated (8 definitive cases, 7 likely cases), excluding potential involvement of denosumab in these cases. Signs associated with potential misdiagnoses of GCTB included poor mineralization with denosumab treatment, rapid relapse in pain, or a failure of the typical dramatic improvement in pain normally observed with denosumab.ConclusionsAlthough rare, GCTB can undergo malignant transformation, and rates in this study were consistent with previous reports. Signs of poor mineralization or lack of response to denosumab treatment may warrant close monitoring.Trial registrationclinicaltrials.gov, (NCT00680992). Registered May 20, 2008.
33 schema:genre article
34 schema:isAccessibleForFree true
35 schema:isPartOf N3ac79929781643b38cfedcfe549022b4
36 Nee1c42841fc34ae691003ba35d552974
37 sg:journal.1024632
38 schema:keywords BackgroundGiant cell tumors
39 ConclusionsAlthough
40 GCTB
41 MethodsThis analysis
42 ResultsTwenty
43 active disease
44 analysis
45 bone
46 cases
47 cell tumors
48 close monitoring
49 course
50 day 8
51 denosumab
52 denosumab 120
53 denosumab treatment
54 disease
55 disease course
56 dose
57 dose of denosumab
58 doses
59 dramatic improvement
60 failure
61 findings
62 giant cell tumor
63 histopathologic reports
64 history
65 imaging
66 improvement
67 involvement
68 lack
69 lack of response
70 malignancy
71 malignant GCTB
72 malignant transformation
73 medical history
74 mineralization
75 misdiagnoses
76 monitoring
77 multicenter study
78 multidisciplinary review
79 open-label phase 2 study
80 pain
81 part
82 patients
83 phase 2
84 phase 2 study
85 poor mineralization
86 post
87 potential cases
88 potential involvement
89 potential misdiagnoses
90 previous reports
91 primary malignant GCTB
92 rapid relapse
93 rate
94 relapse
95 report
96 response
97 review
98 sarcomatous transformation
99 secondary malignant GCTB
100 signs
101 statistical analysis
102 stromal tumors
103 study
104 study day 8
105 transformation
106 treatment
107 tumors
108 weeks
109 schema:name Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab
110 schema:pagination 89
111 schema:productId N9a9d58b4ad254c2ea56a6dd26270a2c8
112 Na8b274f028384b05aab89cdf5d19e1ba
113 Nf7f17dca824447ee951b86b6acb63acf
114 schema:sameAs https://app.dimensions.ai/details/publication/pub.1134796044
115 https://doi.org/10.1186/s12885-020-07739-8
116 schema:sdDatePublished 2022-12-01T06:42
117 schema:sdLicense https://scigraph.springernature.com/explorer/license/
118 schema:sdPublisher Nc354f89939db4c2a8f3d7f12ce78537d
119 schema:url https://doi.org/10.1186/s12885-020-07739-8
120 sgo:license sg:explorer/license/
121 sgo:sdDataset articles
122 rdf:type schema:ScholarlyArticle
123 N05bf52290f8b4fb2806e71dff76b6c9b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Prognosis
125 rdf:type schema:DefinedTerm
126 N175ceccf0dad410ea731f422261b2400 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
127 schema:name Follow-Up Studies
128 rdf:type schema:DefinedTerm
129 N2a00979e149c4681b5e2d8c354add420 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Denosumab
131 rdf:type schema:DefinedTerm
132 N30717925981d47e0b8e3eec64268a190 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Biomarkers, Tumor
134 rdf:type schema:DefinedTerm
135 N34995e42100e4369ab85febb82a50773 rdf:first sg:person.01352077720.12
136 rdf:rest N9c42a1aa98544ea3a6825fcb7654cb20
137 N3ac79929781643b38cfedcfe549022b4 schema:issueNumber 1
138 rdf:type schema:PublicationIssue
139 N4245fe257f7f453a8d029c2a59a73dcd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Middle Aged
141 rdf:type schema:DefinedTerm
142 N5ef46b8c20394c41b7394e29ee69cb3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Female
144 rdf:type schema:DefinedTerm
145 N62c0d39eadbe4f12b7b3bc559e8d2006 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Aged
147 rdf:type schema:DefinedTerm
148 N6e015ce259914c21ae4aaac83a87dbe7 rdf:first sg:person.0753274552.44
149 rdf:rest rdf:nil
150 N6fba124141954c15877fc7ad785f0ff4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Humans
152 rdf:type schema:DefinedTerm
153 N7518d007d8e14f59a43c7fc69196b310 rdf:first sg:person.01111517020.19
154 rdf:rest N7b7e79f57ad04e0888c729971a23adf6
155 N75e85855cbfd48b1a3c7884cb4c3e305 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Aged, 80 and over
157 rdf:type schema:DefinedTerm
158 N7b7e79f57ad04e0888c729971a23adf6 rdf:first sg:person.0760531564.75
159 rdf:rest Nb7b82046a7ab4ca7919bcee92b99f3d0
160 N7ebf944b20c1478183cae6c861f0038f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
161 schema:name Survival Rate
162 rdf:type schema:DefinedTerm
163 N8d1a781c895049269ff60bbf55e7ce95 rdf:first sg:person.016076070467.89
164 rdf:rest Nad8e1d0a44024e9f82888601a8512bcf
165 N9277589216a44ccb8989e3601a693a88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Adolescent
167 rdf:type schema:DefinedTerm
168 N9a9d58b4ad254c2ea56a6dd26270a2c8 schema:name dimensions_id
169 schema:value pub.1134796044
170 rdf:type schema:PropertyValue
171 N9c42a1aa98544ea3a6825fcb7654cb20 rdf:first sg:person.01334463454.00
172 rdf:rest Ne48a8d98e720404bbbd833e9f86f4766
173 Na0eaf2c8fe104cf1af8ec1f94208e3a2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Bone Neoplasms
175 rdf:type schema:DefinedTerm
176 Na8b274f028384b05aab89cdf5d19e1ba schema:name pubmed_id
177 schema:value 33482769
178 rdf:type schema:PropertyValue
179 Nad8e1d0a44024e9f82888601a8512bcf rdf:first sg:person.014366566313.76
180 rdf:rest N6e015ce259914c21ae4aaac83a87dbe7
181 Nb50dafa54c694389b8ee55869aed05bc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Male
183 rdf:type schema:DefinedTerm
184 Nb7b82046a7ab4ca7919bcee92b99f3d0 rdf:first sg:person.01336605441.13
185 rdf:rest N8d1a781c895049269ff60bbf55e7ce95
186 Nbf73ea4f926944a68a86f272f1c8a05e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
187 schema:name Bone Density Conservation Agents
188 rdf:type schema:DefinedTerm
189 Nc354f89939db4c2a8f3d7f12ce78537d schema:name Springer Nature - SN SciGraph project
190 rdf:type schema:Organization
191 Nc53e7441003d4e32aced84792b548ccb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Adult
193 rdf:type schema:DefinedTerm
194 Ne1da1cb81c224893af51aab2f74529c9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
195 schema:name Giant Cell Tumor of Bone
196 rdf:type schema:DefinedTerm
197 Ne48a8d98e720404bbbd833e9f86f4766 rdf:first sg:person.01115347567.94
198 rdf:rest N7518d007d8e14f59a43c7fc69196b310
199 Ned0f4db1f64343a7ba14ddd188ddf03c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
200 schema:name Young Adult
201 rdf:type schema:DefinedTerm
202 Nee1c42841fc34ae691003ba35d552974 schema:volumeNumber 21
203 rdf:type schema:PublicationVolume
204 Nf7f17dca824447ee951b86b6acb63acf schema:name doi
205 schema:value 10.1186/s12885-020-07739-8
206 rdf:type schema:PropertyValue
207 Nfb93d8e3f8ba41de8d3b6b3fde5e947f rdf:first sg:person.01210215667.35
208 rdf:rest N34995e42100e4369ab85febb82a50773
209 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
210 schema:name Medical and Health Sciences
211 rdf:type schema:DefinedTerm
212 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
213 schema:name Clinical Sciences
214 rdf:type schema:DefinedTerm
215 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
216 schema:name Oncology and Carcinogenesis
217 rdf:type schema:DefinedTerm
218 sg:journal.1024632 schema:issn 1471-2407
219 schema:name BMC Cancer
220 schema:publisher Springer Nature
221 rdf:type schema:Periodical
222 sg:person.01111517020.19 schema:affiliation grid-institutes:grid.491869.b
223 schema:familyName Reichardt
224 schema:givenName Peter
225 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01111517020.19
226 rdf:type schema:Person
227 sg:person.01115347567.94 schema:affiliation grid-institutes:grid.419038.7
228 schema:familyName Righi
229 schema:givenName Alberto
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01115347567.94
231 rdf:type schema:Person
232 sg:person.01210215667.35 schema:affiliation grid-institutes:grid.6292.f
233 schema:familyName Palmerini
234 schema:givenName Emanuela
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210215667.35
236 rdf:type schema:Person
237 sg:person.01334463454.00 schema:affiliation grid-institutes:grid.419038.7
238 schema:familyName Gambarotti
239 schema:givenName Marco
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01334463454.00
241 rdf:type schema:Person
242 sg:person.01336605441.13 schema:affiliation grid-institutes:grid.418116.b
243 schema:familyName Blay
244 schema:givenName Jean-Yves
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01336605441.13
246 rdf:type schema:Person
247 sg:person.01352077720.12 schema:affiliation grid-institutes:grid.19006.3e
248 schema:familyName Seeger
249 schema:givenName Leanne L.
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01352077720.12
251 rdf:type schema:Person
252 sg:person.014366566313.76 schema:affiliation grid-institutes:grid.417886.4
253 schema:familyName Jandial
254 schema:givenName Danielle
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014366566313.76
256 rdf:type schema:Person
257 sg:person.016076070467.89 schema:affiliation grid-institutes:grid.417886.4
258 schema:familyName Dai
259 schema:givenName Tian
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016076070467.89
261 rdf:type schema:Person
262 sg:person.0753274552.44 schema:affiliation grid-institutes:grid.6292.f
263 schema:familyName Picci
264 schema:givenName Piero
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0753274552.44
266 rdf:type schema:Person
267 sg:person.0760531564.75 schema:affiliation grid-institutes:grid.19006.3e
268 schema:familyName Bukata
269 schema:givenName Susan
270 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0760531564.75
271 rdf:type schema:Person
272 sg:pub.10.1007/s002640050201 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020784074
273 https://doi.org/10.1007/s002640050201
274 rdf:type schema:CreativeWork
275 sg:pub.10.1007/s00428-009-0863-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020976032
276 https://doi.org/10.1007/s00428-009-0863-2
277 rdf:type schema:CreativeWork
278 sg:pub.10.1007/s00428-012-1198-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1026093835
279 https://doi.org/10.1007/s00428-012-1198-y
280 rdf:type schema:CreativeWork
281 sg:pub.10.1007/s00428-013-1435-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1032421058
282 https://doi.org/10.1007/s00428-013-1435-z
283 rdf:type schema:CreativeWork
284 sg:pub.10.1007/s11864-014-0289-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010580624
285 https://doi.org/10.1007/s11864-014-0289-1
286 rdf:type schema:CreativeWork
287 sg:pub.10.1038/ng.2814 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049677077
288 https://doi.org/10.1038/ng.2814
289 rdf:type schema:CreativeWork
290 sg:pub.10.1186/s12957-018-1478-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1107111968
291 https://doi.org/10.1186/s12957-018-1478-3
292 rdf:type schema:CreativeWork
293 sg:pub.10.1245/s10434-009-0803-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1004194617
294 https://doi.org/10.1245/s10434-009-0803-z
295 rdf:type schema:CreativeWork
296 grid-institutes:grid.19006.3e schema:alternateName David Geffen School of Medicine, UCLA Health System, 200 UCLA Medical Plaza Suite 165-57, 90095, Los Angeles, CA, USA
297 schema:name David Geffen School of Medicine, UCLA Health System, 200 UCLA Medical Plaza Suite 165-57, 90095, Los Angeles, CA, USA
298 rdf:type schema:Organization
299 grid-institutes:grid.417886.4 schema:alternateName Global Development (Oncology), Amgen Inc., One Amgen Center Drive, MS 38-2-B, 91320-1799, Thousand Oaks, CA, USA
300 schema:name Global Development (Oncology), Amgen Inc., One Amgen Center Drive, MS 38-2-B, 91320-1799, Thousand Oaks, CA, USA
301 rdf:type schema:Organization
302 grid-institutes:grid.418116.b schema:alternateName Department of Medical Oncology, Leon Berard Center, 28, rue Laennec 2 69373 Lyon Cedex 08, Lyon, France
303 schema:name Department of Medical Oncology, Leon Berard Center, 28, rue Laennec 2 69373 Lyon Cedex 08, Lyon, France
304 rdf:type schema:Organization
305 grid-institutes:grid.419038.7 schema:alternateName Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
306 schema:name Department of Pathology, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy
307 rdf:type schema:Organization
308 grid-institutes:grid.491869.b schema:alternateName Department of Interdisciplinary Oncology, Sarcoma Center Berlin-Brandenburg; HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany
309 schema:name Department of Interdisciplinary Oncology, Sarcoma Center Berlin-Brandenburg; HELIOS Klinikum Berlin-Buch, Schwanebecker Chaussee 50, 13125, Berlin, Germany
310 rdf:type schema:Organization
311 grid-institutes:grid.6292.f schema:alternateName Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University, 40136, Bologna, Italy
312 schema:name Chemotherapy Unit, IRCCS Istituto Ortopedico Rizzoli, Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Bologna University, 40136, Bologna, Italy
313 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...